Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
GR2303
- Development stage
- Phase 1
- Lead developer
- Zhixiang (Shanghai) Medical Technology
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Administration
- Intravenous
01
Overview
**GR2303** is a monoclonal antibody that inhibits TL1A (TNF-like cytokine 1A, also known as VEGI or Tumor necrosis factor superfamily member 15), a key cytokine involved in inflammatory pathways. Developed initially by Chongqing Genrix Biopharmaceutical Co., Ltd. and now actively advanced by Zhixiang (Shanghai) Medical Technology Co., Ltd., it is in early clinical development primarily for **Inflammatory Bowel Diseases (IBD)** within immune system and digestive system disorders. TL1A inhibition is believed to reduce pro-inflammatory signaling in mucosal tissues, addressing unmet needs in autoimmune gastrointestinal conditions.[1][9][11]
02
Targets
Beyond the preview
Go deeper on GR2303.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on GR2303.